What's really nice is that we're seeing appreciation of stock price with earnings yet to be reported. The higher the stock goes prior to earnings, the greater the thump to higher highs upon their release. The stock is so thinly traded it won't take much to push us over $1.
I'm sure it will dilute. But if that's what it will take to raise cash, so be it. Better than bankruptcy, although I think the CEO would sell out to one of the big players long before that.
The CEO is a scientist, not a business man. It is doable, IF clinical trials are a success and IF he gets the right leadership team in place.
I think last year the CEO said that they expected revenues to double for 2015 and then double again in 2016. It is amazing that the stock is still undiscovered, but great for those of us that got in at these prices (and lower). I was at a conference at which HemaCare had a booth in DC. A Merck rep came over to say that he just placed an order for more material. I got to see their growth and reputation for high quality cell lines in action.
Since you think the stock is going to $300/share in 3 years, I bet you think there will be a lot of movement. If the stock goes to a $1 I will be thrilled. I own a boatload of shares. Let#$%$ a $1 and then go from there. A lot needs to happen for the stock to go to $300. The company will be bought out long before that.
Do you have any idea what Zoom's value proposition is? What makes Zoom unique in the marketplace or what they offer that no one else does? They need to position themselves in terms of either quality, price, or technical features. I'm not sure where they stand.
It's not surprising that Arris/Motorola modems are the top selling modems. They have been at it for quite a while. Zoom really has to focus a specific market niche and provide what we call in my business, a value proposition that is unique, i.e., is different and better than what Arris is doing. They must do this given that they are up against a multi-billion dollar company. And they can do it. Their smallness allows for flexibility that a huge company cannot bring to the marketplace. An example is Apple's phones, versus the small new companies in China that are manufacturing less expensive, high quality, OLED mobile phones. And Apple is feeling the pinch.
However, let me add that what they say during the conference call about the current quarter and upcoming year will be of consequence.
It seems so inconsequential at this point, relative to quarters to come. The real game began on January 1 with the Motorola contract. The next few quarters' results will be interesting, to say the least.